カンナビスベースの治療法による自己免疫疾患とリウマチック疾患の治療の可能性を探る
Inbar Michaeli1, Simon Lassman1, Gilad Halpert2
1Department of Medicine 'B' & The Zabludowiz Center of Autoimmune diseases, Sheba Medical Center, Tel-Hashomer, Israel; Faculty of Medical and Health Sciences, Tel-Aviv University, Israel.
Autoimmunity reviews
|September 4, 2025
まとめ
大麻は自己免疫性疾患やリウマチ症を引き起こす可能性があるが,その医学的な使用を検証するにはより厳密な臨床試験が必要である. 法律や社会的な障壁が 証拠の生成を妨げています
科学分野:
- リウマトロジ
- 免疫学
- 薬理学について
背景:
- 医療大麻に対する世界的な関心が高まっています
- 大麻の治療用途の歴史は,現在の科学的検証が限られていると対照的です.
- カンナビスベースの治療法に関する最新データが必要
研究 の 目的:
- 大麻ベースの治療の潜在的な役割に関する最新のデータを提示する.
- 大麻の効果と安全性を評価する
- 臨床研究における現在の欠陥と課題を強調する.
主な方法:
- 最新の科学文献と臨床データのレビュー
- 大麻ベースの治療の潜在的治療効果と限界の分析
- 臨床試験の実施に影響を与える社会的・法的障壁を特定する.
主要な成果:
- カンナビスは,特定の自己免疫疾患やリウマチ症の治療に有益である可能性があります.
- 医療用大麻の使用を支持する証拠は依然として不十分であり,さらなる検証が必要である.
- 試料の規模が小さいことや 方法論的な弱点によって 予期的な結果が期待できることが多い.
結論:
- 大麻ベースの治療は有望ですが,自己免疫性疾患やリウマチ症に対する強力な科学的証拠は不足しています.
- 医療実践の指針となる高品質の臨床試験が不可欠である.
- この分野での研究を進めるには,社会的・法的障壁を克服することが不可欠です.
関連する概念動画
Autoimmune Disorders
666
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
666
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
200
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
200


